Atossa Genetics Inc has announced that Edward Sauter, MD, PhD, associate dean for research at the University of North Dakota School of Medicine and Health, has joined Atossa’s Scientific Advisory Board.
Atossa Genetics is a a privately-held healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer, including the FDA approved Mammary Aspirate Specimen Cytology Test (MASCT) system.
Dr Sauter is widely recognized for his research and clinical experience in breast cancer. Among his many accomplishments, Dr. Sauter and a team of researchers pioneered noninvasive and minimally invasive techniques to predict breast cancer risk using nipple aspirate fluid (NAF). Dr Sauter is the co-author of over 100 peer-reviewed publications on breast cancer, the majority of which pertain to cytology and molecular diagnostic biomarkers in NAF.
"I am delighted to welcome Dr. Sauter to our Scientific Advisory Board," stated Steven C. Quay, MD, PhD, Chairman, President and CEO.
"Dr Sauter is an accomplished surgeon and breast cancer researcher, and he brings a broad expertise in translational research, developing the results of research into real-world solutions for patients. I look forward to the contributions he will make to the advancement of second-generation breast cancer diagnostic products and services in development at Atossa."
"Early detection of premalignant cells and molecular biomarkers in nipple aspirate fluid provides patients and physicians with important information that may be useful in preventing breast cancer through a personalized medicine approach," commented Dr Sauter. "Atossa’s MASCT System holds promise to serve as an important adjunct to mammography for the benefit of patients."
Source: Atossa Genetics
